Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. SGLT Inhibitors is most often covered alongside FDA, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline.
Last mentioned: Mar 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. SGLT Inhibitors is most often covered alongside FDA, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 5.9 for that window. We currently track 1 Healthcare story that mention SGLT Inhibitors, all published on March 4, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering SGLT Inhibitors. Shared-story counts are live from our verified record — not editorial picks.
Lexicon Pharmaceuticals is set to report its Q4 2025 results, with investors focused on the commercial trajectory of its heart failure drug, Inpefa. The briefing examines the company's path to profitability and the regulatory landscape for its pipeline candidates.
Source: Seeking Alpha · Seeking Alpha
SGLT Inhibitors is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
